Progesterone (Vaginal) | Drug Overview & Clinical Reference
Progesterone (Vaginal)
Clinical safety rating: safe
Vaginal progesterone (200 mg suppository or 90 mg gel) is indicated for prevention of preterm birth in women with singleton pregnancies, no prior preterm birth, and a short cervix (≤25 mm) on transvaginal ultrasound at 16–24 weeks. Also used for luteal phase support in ART pregnancies. The FIGO guideline supports universal cervical length screening and vaginal progesterone treatment. Oral and IM progesterone have different indications and evidence bases.
How it works
Mechanism information is still being processed. Check the DailyMed link in the sidebar for the official prescribing information.
Dosing & administration
Dosing varies by indication and patient profile. Always follow your institution's current prescribing guidelines.
Renal impairment
Consult protocols for adjustment.
Liver impairment
Consult protocols for adjustment.
Use during pregnancy
1st trimester
Safe for luteal support in ART/IVF cycles. No teratogenicity.
2nd trimester
Indicated for cervical length <25 mm to reduce preterm birth risk.
3rd trimester
Discontinue at 36–37 weeks per most protocols.
Clinical note
Vaginal progesterone (200 mg suppository or 90 mg gel) is indicated for prevention of preterm birth in women with singleton pregnancies, no prior preterm birth, and a short cervix (≤25 mm) on transvaginal ultrasound at 16–24 weeks. Also used for luteal phase support in ART pregnancies. The FIGO guideline supports universal cervical length screening and vaginal progesterone treatment. Oral and IM progesterone have different indications and evidence bases.
Breastfeeding
Safe. Progesterone is a natural hormone; vaginal formulations with minimal systemic absorption are compatible with breastfeeding.
Warnings & precautions
When not to use it
Avoid in patients with known hypersensitivity to this drug or any of its components.
